Instiladrin and Rebiotix

[anonymous]

Spoke with one of my urologist who happens to be a investigator for Instiladrin. He said the trial is taking longer than expected but results look awesome. Said it’s a winner

? A KAD, actually out making a call. I don't believe it.

 

[anonymous]

? A KAD, actually out making a call. I don't believe it.

you’re funny. Now go drop off some samples and buy pizza for a bunch of receptionists. Great job r*****. Hahaha.

 

[anonymous]

Interesting yes
Seres has their CLO, and the other two have their CEO. Sort of seems a backhand by the Seres CEO.

Any word on how these three companies, or others are “fairing” in this C diff space?

 

[anonymous]

what ever they say must be taken in the context of earnings per share which Ferring doesn't care about. We don't report anything which is a big competitive advantage.

 

[anonymous]

what ever they say must be taken in the context of earnings per share which Ferring doesn't care about. We don't report anything which is a big competitive advantage.

With home office imploding, poor moral with DMs and sales, bad history of launches...where is the big advantage.

 

[anonymous]

With home office imploding, poor moral with DMs and sales, bad history of launches...where is the big advantage.

No therapy based on fecal transplant for C diff is going to be approved any time soon. With the bad phase 2 results for both Rebiotix and Seres, heavy scrutiny to be had on the first phase 3.

I still can’t figure out why Ferring bought such a POS.

 

[anonymous]

https://www.ncbi.nlm.nih.gov/m/pubmed/29617739/#fft

 

[anonymous]

Theranos mark2

Ferring must have talked with Walgreens?

 

[anonymous]

what are you talking about you tard

 

[anonymous]

I think they are saying:
Ferring =Walgreens
Rebiotix = Theranos

 

[anonymous]

this makes business sense because executive management decision to inculcate units P&Ls to ensure cash flows reserve. Thanks for sharing

 

[anonymous]

This is why the FDA will never approve a product like RBX2660

https://www.jwatch.org/fw115524/2019/06/17/patient-dies-after-receiving-fecal-transplant-contained

 

[anonymous]

This is why the FDA will never approve a product like RBX2660

https://www.jwatch.org/fw115524/2019/06/17/patient-dies-after-receiving-fecal-transplant-contained

Hey genius, this is exactly why it will get approval. Today fecal matter products are used by hundreds of hospitals without proper studies proving safety efficacy or quality. FDA wants approval hence fast track designation. Leave the thinking to the big boys and go back out and drop your samples

 

[anonymous]

Hey genius, this is exactly why it will get approval. Today fecal matter products are used by hundreds of hospitals without proper studies proving safety efficacy or quality. FDA wants approval hence fast track designation. Leave the thinking to the big boys and go back out and drop your samples

Almost all of the safety issue is the donor and donor “material”. Tall order. It revolves around testing donor blood and stool. Sample integrity and Testing for resistant organisms is not an easy matter. Not enough control. Fucking nightmare. Another HIV/Factor 8 waiting to happen.

 

[anonymous]

speaking of FDA and fecal materials you strike me as a silly poopy head. Hahaha I made a funny! And your fingers smell

 

[anonymous]

Adstilidrin and rebiota are the future of this organization. This company needs them both to succeed. Adstilidrin should be a game changer. Rebiota could also have multiple indications in the future like Botox.

 

[anonymous]

Hey Genius, what happens if neither get approved? Menopur still has no competition with none expected in the future.